PT Falmaco Nonwoven Industri Tbk is a leading manufacturer of nonwoven fabrics in Indonesia, primarily serving the household and personal products sectors. The company operates several production facilities across Java, providing a diverse range of products including hygiene materials and medical textiles, which are critical in the growing healthcare market.
Falmaco generates revenue through the production and sale of nonwoven fabrics, leveraging its advanced manufacturing capabilities and established relationships with major retailers and healthcare providers. The company benefits from economies of scale and a strong distribution network, allowing it to maintain competitive pricing despite rising raw material costs.
Changes in raw material prices, particularly polypropylene and polyester, which directly impact production costs.
Demand fluctuations in the hygiene and medical sectors, driven by consumer trends and healthcare needs.
Regulatory changes affecting the production and use of nonwoven materials in medical applications.
Expansion into new markets or product lines, particularly in Southeast Asia.
Technological disruption from alternative materials or production methods that could reduce demand for nonwovens.
Regulatory changes regarding environmental impacts of nonwoven production.
Intensifying competition from both local and international nonwoven manufacturers.
Price competition leading to margin compression.
Negative cash flow trends, with operating cash flow at -$1.2B, raising concerns about liquidity.
Potential challenges in managing capital expenditures, which are currently at $1.2B.
moderate - the company's performance is linked to consumer spending and healthcare demand, which can be cyclical.
The company's financing costs may rise with increasing interest rates, impacting capital expenditures and potentially slowing growth initiatives.
minimal - the company has a relatively low debt-to-equity ratio of 0.35, indicating limited reliance on external financing.
growth - investors may be drawn to potential recovery in revenue and margins as the company stabilizes operations.
high - the stock has shown significant price volatility, with a 1-year return of 107.5% but a 6-month return of -38.2%.